1195 KB42 KB200520252020Bratkovič, TomažLovšin, NikaLunder, Mojcaštevilka:2letnik:71str. 163-173ISSN:0014-8229COBISSID_HOST:20559875URN:URN:NBN:SI:doc-Z4ZG78N5slSlovensko farmacevtsko društvoFarmacevtski vestnikCepivapandemija covid-19PandemijeSARS-CoV-2Razvoj cepiv proti virusu SARS-CoV-2| SARS-CoV-2 vaccine pipeline|The enormous impact of covid-19 pandemic on everyday life, global economy and healthcare has stimulated the fast-tracked development of SARS-CoV2 vaccines. Development is directed also towards promising innovative although not yet established platforms, such as vector vaccines and DNA and RNA-based vaccines. The SARS-CoV-2 vaccine development is projected to cost about 2 billion USD and take 12 to 18 months. 115 vaccines are currently being developed, of which 73 are in the preclinical phase and 10 in the first or second stage of a clinical trials. Only the results of the third stage of trials, which will include thousands of volunteers and their longterm monitoring, will give an answer as to whether the vaccine achieves the desired protection against the pathogen. On the way to the ultimate goal of a safe, effective and accessible vaccine, significant barriers to cost-effective production will still need to be overcome, especially for new platforms for which production infrastructure does not yet existPandemija bolezni covid-19 je vplivala na življenje ljudi, na svetovno gospodarstvo in zdravstvo in tako spodbudila pospešen razvoj cepiv proti virusu SARSCoV-2. Razvoj gre tudi v smer uporabe obetavnih inovativnih, a še neuveljavljenih platform, kot so vektorska cepiva ter cepiva na osnovi DNA in RNA. Predvidevajo, da bo razvoj cepiva stal okoli 2 milijardi dolarjev in trajal od 12 do 18 mesecev. Trenutno poteka razvoj 115 cepiv, od tega jih je 73 v predklinični fazi, 10 pa v prvi ali drugi stopnji kliničnega preskušanja. Šele rezultati tretje stopnje preskušanj, ki bodo vključevali več tisoč prostovoljcev in njihovo dolgoročno spremljanje, bodo dali odgovor, ali s cepivom dosežemo želeno zaščito pred patogenom. Na poti do končnega cilja varnega, učinkovitega in vsem dostopnega cepiva bo potrebno zaobiti še precejšnje ovire, povezane tudi s stroškovno učinkovito proizvodnjo, predvsem pri novih platformah, pri katerih proizvodna infrastruktura še ne obstajaTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko farmacevtsko društvo